YANG Min
Principal Investigator
Dr. Yang graduated from Peking University in 2007, and went to University of Pittsburgh Medical Center as a visiting scholar. She owns the title of Beijing Nova Program and High-level Elite Scientist in the health sector. She is a member of the ICH non-clinical safety trials expert group and principal investigator of a number of national projects. In 2013, she won the first prize of the 24th Great Wall International Conference of Cardiology - Chinese American Heart Association. Currently, Dr. Yang has published 39 SCI papers, including 14 first-author and corresponding-author papers. Dr. Yang Min's research interest is in tumor biomarker, the mechanism of tumor metastasis, and molecular targets for cardiovascular remodeling.
1. Lp-PLA2 inhibition prevents Ang II–induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation. Acta Pharmacologica Sinica, 2021. DOI: 10.1038/s41401-021-00703-7
2. YHigh SEMA4C expression promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal carcinoma. Aging-US, 2020. 12(21): 21992-22018.
3. Indoleamine 2, 3-dioxygenase 1 (IDO1) and CD8 expression profiling revealed an immunological subtype of colon cancer with a poor prognosis. Frontiers in Oncology, 2020. 12. doi: 10.3389
4. A bioinformatics analysis on the potential role of ACE2 in cardiac impairment of patients with coronavirus disease 2019. Annals of Translational Medicine, 2020. 8(21): 1403
5. Prognostic significance of mutant-allele tumor heterogeneity in uterine corpus endometrial carcinoma. Annals of Translational Medicine, 2020. 8(6):339
6. The SGK1 inhibitor EMD638683, prevents Angiotensin II-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation. Biochimica et Biophysica Acta-Molecular Basis of Disease, 2018. 1864(1):1-10.
7. Serum-glucocorticoid-regulated kinase 1 contributes to mechanical stretch-induced inflammatory responses in cardiac fibroblasts. Molecular and Cellular Biochemistry, 2018. 445(1-2): 67-78.
8. Macrophage phenotypic subtypes diametrically regulate epithelial-mesenchymal plasticity in breast cancer cells. BMC Cancer, 2016. 16: 419.
9. ICAM-1 suppresses tumor metastasis by inhibiting macrophage M2 polarization through blockade of efferocytosis. Cell Death & Disease, 2015. 6: e1780.
10. Tumor cell-activated CARD9 signaling contributes to metastasis-associated macrophage polarization. Cell Death & Differentiation, 2014. 21(8):1290-1302.
11. Cathepsin S-mediated autophagic flux in tumor-associated macrophages accelerate tumor development by promoting M2 polarization. Molecular Cancer, 2014. 13:43. doi:10.1186/1476-4598-13-43.
12. Chemokine receptor CX3CR1 contributes to macrophage survival in tumor metastasis. Molecular Cancer, 2013. 12(1):141.
13. Serum-glucocorticoid regulated kinase 1 regulates alternatively activated macrophage polarization contributing to angiotensin II-induced inflammation and cardiac fibrosis. Arteriosclerosis Thrombosis & Vascular Biology, 2012. 32:1675-1686.
14. Ghrelin inhibits apoptosis signal-regulating kinase 1 activity via upregulating heat shock protein 70. Biochemical and Biophysical Research Communications, 2007. 359:373-378.
